20-22 March 2018

London, UK

Previous Speakers

Expand/Collapse

Helen Tayton-Martin
COO
Adaptimmune

Day One

Wednesday 8th March 2017

10.00 | NYO-ESO TCR trial Update and Advances with MAGE A4 TCR

Christoper Bunker
Vice President, Business Development
Advanced Cell Diagnostics

Day One

Wednesday 8th March 2017

14.30 | Expanding CDx Strategy Options with RNAscope®, A Clinically-Validated, Quantitative in situ RNA Biomarker Platform

Thorsten Gantke
Project Leader, Research & Development
Affimed

Day Two

Thursday 9th March 2017

10.00 | AFM13: A Bispecific NK-Cell Engager Modulating Innate and Adaptive Immunity

Nina Kotsopoulou
Head Process Development
Autolus

Day One

Wednesday 8th March 2017

18.00 | PANEL: The Future of Cell Therapy Commercialization

Aaron Foster
VP, Product Discovery
Bellicum Pharmaceuticals

Day Two

Thursday 9th March 2017

09.00 | Bellicum Case Study

Sarah Sheridan
Principal Scientist, EMEA, Field Development Services
Merck, BioReliance® Services

Day Two

Thursday 9th March 2017

16.30 | Cell and Gene Therapy Safety Testing Regulations and Requirements: Guidance and Advice for Clinical Success

Kevin Friedman
Director, Cell Immunotherapy
bluebird bio

Day One

Wednesday 8th March 2017

09.00 | Further Development of CAR T Cells for Treatment of Cancer

Travis Young
Principal Investigator
CALIBR

Day Two

Thursday 9th March 2017

11.30 | Control of CAR-T Cell Therapy Using Bio-Orthogonal Switches

Jens Hasskarl
Senior Medical Director, Clinical Research & Development
Celgene

Day One

Wednesday 8th March 2017

18.00 | PANEL: The Future of Cell Therapy Commercialization

Day Two

Thursday 9th March 2017

09.30 | Celgene Case Study

David Sourdive
Co-Founder & EVP, Corporate Development
Cellectis

Day One

Wednesday 8th March 2017

18.00 | PANEL: The Future of Cell Therapy Commercialization

Day Two

Thursday 9th March 2017

15.30 | Autologous vs. Allogeneic “Off-the-Shelf” Therapy Manufacturing

Wilfred Germeraad
CSO
CiMaas

Day One

Wednesday 8th March 2017

15.00 | Translating University Research into a Viable and Effective Product for Cancer Patients

Stephan Grupp
Director, Cancer Immunotherapy Program
CHOP

Day One

Wednesday 8th March 2017

19.00 | Chairman’s Closing Remarks and Close of Day One

08.30 | Chairman’s Opening Remarks

Day Two

Thursday 9th March 2017

18.00 | Chairman’s Closing Remarks and Close of Summit

08.30 | Chairman’s Opening Remarks

Cheng Liu
CEO
Eureka Therapeutics

Day One

Wednesday 8th March 2017

11.30 | Targeting The “Untargetable” Solid Tumour Antigens

Bob Valamehr
Executive Director, Reprogramming Biology
Fate Therapeutics

Day One

Wednesday 8th March 2017

18.00 | PANEL: The Future of Cell Therapy Commercialization

Day Two

Thursday 9th March 2017

14.30 | Using Engineered Pluripotent Cells as a Renewal Source for Off-the-Shelf Cancer Immunotherapy

Yannick Bulliard
Director, Product Science
Immatics Biotechnologies

Day One

Wednesday 8th March 2017

12.00 | XPRESIDENT®-Guided Target Identification and Profiling of On- and Off-Target Toxicity for Safer Adoptive Cell Therapy

Thomas Duensing
Chief Technology Officer
IntelliCyt

Day One

Wednesday 8th March 2017

16.00 | Advancing the Discovery of Immunotherapeutics with Large Scale, Multiplexed Experiments on Cells and Proteins of Immune System

Evren Alici
Group Leader, Cell & Gene Therapy
Karolinska Institutet

Day Two

Thursday 9th March 2017

15.00 | How to Get Cell Immunotherapies to the Clinic Commercially

John Maher
CSO
Leucid Bio

Day One

Wednesday 8th March 2017

17.30 | CAR Mechanics Research Group: Clinical Case Study of Intra- Tumoural CAR-T Cell Therapy in Head and Neck Cancer

Lotte Wieten
Assistant Professor Immunology
Maastricht University Medical Center

Day One

Wednesday 8th March 2017

17.00 | Natural Killer Cell Immunotherapy: Development of Clinically Effective Strategies to Unleash the Killer Within

Rolf Ehrhardt
President and Chief Executive Officer
Medcision

Day Two

Thursday 9th March 2017

14.00 | Automation and Process Management Technologies for the Clinic

Christiane Niederlaender
CAT Member, Senior Quality Assessor
UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Workshop A: Held at Hallam Conference Centre

Tuesday 7th March 2017

09.00 |
Cell Therapy Regulations, Pricing & Reimbursement

Day Two

Thursday 9th March 2017

17.00 | Regulatory and Scientific Considerations on Adoptive Immunotherapies: The View of the Committee for Advanced Therapies

Hans-Guido Wendel
Associate Member
Memorial Sloan Kettering Cancer Center

Day Two

Thursday 9th March 2017

12.00 | Restoring Tumour Suppression with CAR-T Micro-Pharmacies

Steven Feldman
Director, Surgery Branch Vector Production Facility
NCI

Day One

Wednesday 8th March 2017

13.00 | Treatment of Solid Cancers by Adoptive Cell Transfer of Tumor- Infiltrating Lymphocytes Targeting Mutated Tumor Antigens

Samuele Butera
Global Cell & Gene Therapies Business Leader
Novartis

Day Two

Thursday 9th March 2017

10.30 | The Globalization of CAR-T Therapy

Bijan Boldajipour
Tumor Immunologist
Pfizer/Rinat

Day One

Wednesday 8th March 2017

18.00 | PANEL: The Future of Cell Therapy Commercialization

09.30 | Preclinical Evaluation of Allogeneic Anti-BCMA Chimeric Antigen Receptor T Cells

Bruce Thompson
Sr. Principal Scientist, Biotherapeutics Pharmaceutical Sciences
Pfizer

Workshop B: Held at Hallam Conference Centre

Tuesday 7th March 2017

13.00 |
Overcoming Bioprocessing Challenges for Cell & Gene Therapy Products

Aino Kalervo
Head, Business Management
TILT Biotherapeutics

Day Two

Thursday 9th March 2017

12.30 | Enabling T-Cell Therapies for Solid Tumours with Oncolytic Immunotherapy

Avery Posey
Instructor, June Lab
UPenn

Day One

Wednesday 8th March 2017

15.30 | Man’s Best Friend and the Contribution to Cellular Therapy Development

Will Green
Senior Research Consultant, York Health Economics Consortium
University of York

Workshop A: Held at Hallam Conference Centre

Tuesday 7th March 2017

09.00 |
Cell Therapy Regulations, Pricing & Reimbursement

Day Two

Thursday 9th March 2017

17.30 | The Health Economics of Adoptive Immunotherapies

Laurence Cooper
Chief Executive Officer
ZIOPHARM

Day One

Wednesday 8th March 2017

12.30 | Broadening the Appeal of T-Cell Therapeutics to Target Tumour